1. Pink Sheet

COVID-19 Lesson: India Earmarks $1.3bn To Reduce Dependence On China

Lopinavir, Ritonavir On List Of 53 Incentivized APIs

 
• By Vibha Ravi

In a bid to ensure long-term medicines security, the Indian government has earmarked $1.32bn to promote domestic production of 53 APIs, including lopinavir and ritonavir currently being evaluated to treat COVID-19 cases, as well as antibiotics, for which India is highly dependent on China.

Drawing_Domino_Effect
India Aims To Reduce Its Supply Chain Vulnerability Post The COVID-19 Crisis • Source: Shutterstock

The COVID-19 pandemic has proven to be the wake-up call that India, heavily dependent on China for pharmaceutical raw material supplies, needed to build its defense. As the world fights a massive health challenge that has so far affected over 170 countries and territories, forcing several into lock-downs and making "social distancing" part of daily life, India has acted on a long-standing problem.

In a INR99.4bn ($1.3bn) stimulus, the union cabinet recently approved incentivizing the production of 53 critical active pharmaceutical ingredients (APIs)...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Safety

More from Pink Sheet

US FDA To Advisory Committee Industry Reps: Don’t Talk Too Much

 
• By Sue Sutter

Nonvoting industry representative’s presence at Pediatric Advisory Committee meeting was required by statute, the agency said, a de facto acknowledgement that an April directive precluding industry reps from sitting on advisory committees has had little practical effect.

New US FDA Biologics License Pathway Could Be Missing Link To Reduce Animal Testing

 
• By Bridget Silverman

Akin to the 505(b)(2) NDA, a new biologic pathway could reduce the need for animal testing, FDA toxicologist says. Expanded use of generally accepted scientific knowledge (GASK), which few sponsors have attempted despite a 2023 draft guidance, would also help.

Capricor Gets Complete Response For DMD Cell Therapy: Unconvincing Data Or New Attitude At FDA?

 
• By Joseph Haas

Seven weeks before its action date and a month after an advisory committee was hastily cancelled, Capricor gets a CRL for its cell therapy deramiocel in DMD-related cardiomyopathy citing efficacy and manufacturing concerns. It has a Phase III study nearing readout, though.